SCHEMBL5263205

SCHEMBL5263205

CC(NC(=O)c1nc2ccccc2s1)C(Cc1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.57
TSHR P16473 1/20 0.57
CASP1 P29466 1/20 0.57
FDFT1 P37268 2/20 0.50
CCR1 P32246 1/20 0.49
CNR1 P21554 13/20 0.49
CNR2 P34972 10/20 0.49
FFAR2 O15552 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
MEN1 O00255 1/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
CRHBP P24387 1/20 0.46
HTT P42858 1/20 0.46
KMT2A Q03164 1/20 0.46
CRHR2 Q13324 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3524036 0.83 CCR1 (0.54) TSHRFDFT1CCR1MEN1PKM
SCHEMBL13804711 0.83 CCR1 (0.54) TSHRFDFT1CCR1MEN1PKM
SCHEMBL3526373 0.82 MAPT (0.51) ALOX15TSHRFDFT1CNR1CNR2
SCHEMBL13804745 0.82 MAPT (0.51) ALOX15TSHRFDFT1CNR1CNR2
SCHEMBL5264318 0.81 ALOX15 (0.56) ALOX15TSHRCASP1CCR1CNR1
SCHEMBL5262773 0.78 CNR1 (0.72) FDFT1CNR1CNR2
SCHEMBL5265141 0.77 CNR1 (0.49) FDFT1CNR1CNR2FFAR2KMT2A
SCHEMBL5261127 0.77 CNR1 (0.49) FDFT1CNR1CNR2
SCHEMBL5262269 0.77 CNR1 (0.63) FDFT1CNR1CNR2MEN1HTT
SCHEMBL5260009 0.77 FDFT1 (0.68) FDFT1CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1494997-A4 SUBSTITUTED ARYL AMIDES MERCK & CO INC (US) 2007-04-11 EP claimed
JP-2005527586-A 2005-09-15 JP claimed
US-20050154202-A1 Substituted aryl amides MERCK & CO., INC. 2005-07-14 US claimed
EP-1494997-A1 SUBSTITUTED ARYL AMIDES Merck & Co., Inc. (US) 2005-01-12 EP claimed
WO-2003087037-A1 SUBSTITUTED ARYL AMIDES MERCK & CO., INC. (US) 2003-10-23 WO claimed
EP-1494997-A4 SUBSTITUTED ARYL AMIDES MERCK & CO INC (US) 2007-04-11 EP disclosed
US-20050154202-A1 Substituted aryl amides MERCK & CO., INC. 2005-07-14 US disclosed
EP-1494997-A1 SUBSTITUTED ARYL AMIDES Merck & Co., Inc. (US) 2005-01-12 EP disclosed
WO-2003087037-A1 SUBSTITUTED ARYL AMIDES MERCK & CO., INC. (US) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154202-A1 Substituted aryl amides CNR1, CNR2, FAAH ALOX15 432/4885TSHR 566/4885CASP1 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.